详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Poly(ADP-ribose) polymerase inhibitors in cancer therapy

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ 卓越：领军期刊 ◇ 中华系列

作者：

机构： [1]Department of Pathology & Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. [2]Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

出处：

DOI：

ISSN：

关键词： Poly(ADP-ribose) polymerase inhibitors DNA repair Cell death BRCA Synthetic lethal mutations Ovarian cancer Prostate cancer Breast cancer Carcinoma non-small-cell lung Pancreatic cancer

摘要：

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death, particularly in cancer cells with homologous recombination repair deficiencies, such as those harboring BRCA mutations. This review delves into the mechanisms of action of PARPis in anticancer treatments, including the inhibition of DNA repair, synthetic lethality, and replication stress. Furthermore, the clinical applications of PARPis in various cancers and their adverse effects as well as their combinations with other therapies and the mechanisms underlying resistance are summarized. This review provides comprehensive insights into the role and mechanisms of PARP and PARPis in DNA repair, with a particular focus on the potential of PARPi-based therapies in precision medicine for cancer treatment.Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区医学：内科

第一作者：

第一作者机构： [1]Department of Pathology & Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. [2]Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

通讯作者：

通讯机构： [1]Department of Pathology & Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. [2]Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China [2]190P Real world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: a single-center study in China [3]Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. [4]Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. [5]Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy [6]The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis [7]Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment [8]Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer [9]非小细胞肺癌ERCC1表达与铂类药物疗效相关性的荟萃分析 [10]Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer